(S)-Gossypol (acetic acid) (Synonyms: (S)-(+)-Gossypol acetic acid)

目录号: HY-15464D 纯度: 98.39%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

(S)-Gossypol acetic acid 是天然产物 Gossypol 的异构体。(S)-Gossypol 以高亲和力结合到 Bcl-xL 和 Bcl-2 蛋白的 BH3 结合沟。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

(S)-Gossypol (acetic acid) Chemical Structure

CAS No. : 1189561-66-7

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥1540	In-stock
5 mg	￥875	In-stock
10 mg	￥1400	In-stock
50 mg	￥4000	In-stock
100 mg	现货	询价
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of (S)-Gossypol (acetic acid):

MCE 顾客使用本产品发表的 3 篇科研文献

(S)-Gossypol (acetic acid) 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Bcl-2 Family 亚型特异性产品:

查看所有亚型

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

(S)-Gossypol is the isomer of a natural product Gossypol. (S)-Gossypol binds to the BH3-binding groove of Bcl-xL and Bcl-2 proteins with high affinity.

IC₅₀ & Target^[1]

Bcl-2

Bcl-xL

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
4T1	IC₅₀	18.78 μM Compound: 1	Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay	[PMID: 20684596]
4T1	IC₅₀	21.53 μM Compound: 2	Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay Cytotoxicity against mouse 4T1 cells after 72 hrs by MTT assay	[PMID: 20684596]
A549	IC₅₀	1.32 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20684596]
A549	IC₅₀	33.08 μM Compound: 2	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20684596]
B16-F10	IC₅₀	17.97 μM Compound: 2	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 20684596]
B16-F10	IC₅₀	5.54 μM Compound: 1	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 20684596]
B16-F10	IC₅₀	5.56 μg/mL Compound: (R)-Gossypol	Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay	[PMID: 22739087]
Cancer cell lines	GI₅₀	2.85 μM Compound: (+/-)-Gossypol	Cytotoxicity against human non-small cell lung cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human non-small cell lung cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	2.97 μM Compound: (+/-)-Gossypol	Cytotoxicity against human CNS cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human CNS cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	3.16 μM Compound: (+/-)-Gossypol	Cytotoxicity against human renal cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human renal cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	3.19 μM Compound: (+/-)-Gossypol	Cytotoxicity against human colon cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human colon cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
Cancer cell lines	GI₅₀	3.5 μM Compound: (+/-)-Gossypol	Cytotoxicity against human ovarian cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human ovarian cancer cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
CT26	IC₅₀	13.59 μM Compound: 2	Cytotoxicity against mouse CT26 cells after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells after 72 hrs by MTT assay	[PMID: 20684596]
CT26	IC₅₀	2.21 μM Compound: 1	Cytotoxicity against mouse CT26 cells after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells after 72 hrs by MTT assay	[PMID: 20684596]
CT26	IC₅₀	23.2 μM Compound: (-)-Gossypol	Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
CT26	IC₅₀	46.78 μM Compound: (+/-)-Gossypol	Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
CT26	IC₅₀	61.9 μM Compound: (+)-Gossypol	Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse CT26 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
DU-145	IC₅₀	19.17 μM Compound: (+)-Gossypol	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
DU-145	IC₅₀	7.93 μM Compound: (+/-)-Gossypol	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
DU-145	IC₅₀	7.97 μM Compound: (-)-Gossypol	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
HCT-116	IC₅₀	21.99 μM Compound: 2	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20684596]
HCT-116	IC₅₀	3.03 μM Compound: (+/-)-Gossypol	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
HCT-116	IC₅₀	3.33 μM Compound: 1	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20684596]
HCT-116	IC₅₀	3.59 μM Compound: (-)-Gossypol	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
HCT-116	IC₅₀	5.01 μM Compound: (+)-Gossypol	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
HEK293	IC₅₀	11.04 μM Compound: AT-101	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27353532]
HeLa	IC₅₀	0.08 μg/mL Compound: 18	Cytotoxicity against human HeLa cells by SRB assay Cytotoxicity against human HeLa cells by SRB assay	[PMID: 18553924]
HeLa	IC₅₀	17.8 μM Compound: (-)-Gossypol	Anticancer activity against human HeLa cells after 48 hrs by MTT assay Anticancer activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19447525]
HeLa	IC₅₀	31.3 μM Compound: (+)-Gossypol	Anticancer activity against human HeLa cells after 48 hrs by MTT assay Anticancer activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19447525]
HepG2	IC₅₀	10.16 μg/mL Compound: (R)-Gossypol	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22739087]
HL-60	IC₅₀	6.6 μM Compound: AT-101	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27353532]
HT-29	IC₅₀	> 5 μg/mL Compound: 18	Cytotoxicity against human HT29 cells by SRB assay Cytotoxicity against human HT29 cells by SRB assay	[PMID: 18553924]
K562	IC₅₀	4.55 μM Compound: (R)-Gossypol	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 25818766]
K562	IC₅₀	5.6 μM Compound: Gossypol	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 27810438]
K562	IC₅₀	5.91 μM Compound: Gossypol	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 26620718]
K562	IC₅₀	7.31 μM Compound: Gossypol	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 26421995]
K562	IC₅₀	8.28 μM Compound: (-)-(R)-Gossypol	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28233676]
KB	IC₅₀	0.04 μg/mL Compound: 18	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 18553924]
Leukemia cell	GI₅₀	2.47 μM Compound: (+/-)-Gossypol	Cytotoxicity against human leukemia cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human leukemia cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
MCF7	IC₅₀	12.58 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20684596]
MCF7	IC₅₀	21.56 μM Compound: 2	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20684596]
MCF7	IC₅₀	54 μM Compound: (-)-Gossypol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
MCF7	IC₅₀	60.1 μM Compound: (+/-)-Gossypol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
MCF7	IC₅₀	75 μM Compound: (+)-Gossypol	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27994761]
MDA-MB-231	IC₅₀	1.9 μM Compound: 1	Growth inhibition of human MDA-MB-231 cells after 4 days by WST-based assay Growth inhibition of human MDA-MB-231 cells after 4 days by WST-based assay	[PMID: 17552510]
MDA-MB-231	IC₅₀	3.7 μM Compound: 2, R-(-)-gossypol	Growth inhibition of human MDA-MB-231 2LMP cells after 4 days by WST-8 based assay Growth inhibition of human MDA-MB-231 2LMP cells after 4 days by WST-8 based assay	[PMID: 18237106]
MDA-MB-231	IC₅₀	4.8 μM Compound: Gossypol	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 26421995]
MDA-MB-231	IC₅₀	8.54 μM Compound: (-)-(R)-Gossypol	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28233676]
MDA-MB-231	IC₅₀	9.21 μM Compound: (R)-Gossypol	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25818766]
MDA-MB-231	IC₅₀	9.23 μM Compound: Gossypol	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 27810438]
MDA-MB-231	IC₅₀	9.42 μM Compound: Gossypol	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26620718]
MDA-MB-435	IC₅₀	11.78 μM Compound: 1	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 20684596]
MDA-MB-435	IC₅₀	33.25 μM Compound: 2	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 20684596]
MDCK	IC₅₀	1.87 μM Compound: (+)-Gossypol	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay	[PMID: 23538114]
MDCK	CC₅₀	3.53 μM Compound: (+)-Gossypol	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 23538114]
MDCK	CC₅₀	3.53 μM Compound: Gossypol	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 22226654]
MDCK	IC₅₀	3.82 μM Compound: (-)-Gossypol	Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay Antiviral activity against Influenza A virus (A/Vietnam/1194/2004(H5N1)) infected in MDCK cells by plaque reduction assay	[PMID: 23538114]
MDCK	CC₅₀	35.35 μM Compound: (-)-Gossypol	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 23538114]
Melanoma cell	GI₅₀	3.22 μM Compound: (+/-)-Gossypol	Cytotoxicity against human melanoma cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human melanoma cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 27994761]
NCI-H1299	EC₅₀	6 μM Compound: 1, Gossypol	Cytotoxicity against human H1299 cells assessed as cell viability after 72 hrs by ATP-LITE assay Cytotoxicity against human H1299 cells assessed as cell viability after 72 hrs by ATP-LITE assay	[PMID: 19555126]
NCI-H460	EC₅₀	3 μM Compound: 1, Gossypol	Cytotoxicity against human H460 cells assessed as cell viability after 72 hrs by ATP-LITE assay Cytotoxicity against human H460 cells assessed as cell viability after 72 hrs by ATP-LITE assay	[PMID: 19555126]
PC-3	EC₅₀	17.8 μM Compound: (+)-1	Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay	[PMID: 20443627]
PC-3	IC₅₀	2.5 μM Compound: 2, R-(-)-gossypol	Growth inhibition of human PC3 cells after 4 days by WST-8 based assay Growth inhibition of human PC3 cells after 4 days by WST-8 based assay	[PMID: 18237106]
PC-3	IC₅₀	22.36 μM Compound: 2	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20684596]
PC-3	EC₅₀	3.3 μM Compound: (-)-1	Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay Cytotoxicity against human PC3 cells after 3 days by ATP-LITE assay	[PMID: 20443627]
PC-3	IC₅₀	5.61 μM Compound: Gossypol	Antiproliferative activity against human PC3 cells by MTT assay Antiproliferative activity against human PC3 cells by MTT assay	[PMID: 26421995]
PC-3	IC₅₀	5.78 μM Compound: Gossypol	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26620718]
PC-3	IC₅₀	6.26 μM Compound: (R)-Gossypol	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25818766]
PC-3	IC₅₀	6.71 μg/mL Compound: (R)-Gossypol	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 22739087]
PC-3	IC₅₀	7.54 μM Compound: Gossypol	Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay	[PMID: 27810438]
PC-3	IC₅₀	8.58 μM Compound: (-)-(R)-Gossypol	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28233676]
PC-3	IC₅₀	9.14 μM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20684596]
SW-620	IC₅₀	12.58 μM Compound: 1	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 20684596]
SW-620	IC₅₀	21.56 μM Compound: 2	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 20684596]
TZM	CC₅₀	18.12 μM Compound: (+)-Gossypol	Cytotoxicity against human TZM-bl cells after 72 hrs by MTT assay Cytotoxicity against human TZM-bl cells after 72 hrs by MTT assay	[PMID: 29162455]
TZM	CC₅₀	5.22 μM Compound: (-)-Gossypol	Cytotoxicity against human TZM-bl cells after 72 hrs by MTT assay Cytotoxicity against human TZM-bl cells after 72 hrs by MTT assay	[PMID: 29162455]
TZM	CC₅₀	9.76 μM Compound: Gossypol	Cytotoxicity in human TZM-bl cells by MTT assay Cytotoxicity in human TZM-bl cells by MTT assay	[PMID: 22226654]
U-87MG ATCC	IC₅₀	30.2 μM Compound: (-)-Gossypol	Anticancer activity against human U87 cells after 48 hrs by MTT assay Anticancer activity against human U87 cells after 48 hrs by MTT assay	[PMID: 19447525]
U-87MG ATCC	IC₅₀	59.6 μM Compound: (+)-Gossypol	Anticancer activity against human U87 cells after 48 hrs by MTT assay Anticancer activity against human U87 cells after 48 hrs by MTT assay	[PMID: 19447525]

体外研究
(In Vitro)

The natural racemic Gossypol has two enantiomers, namely the (-)-Gossypol and (S)-Gossypol ((+)-Gossypol) enantiomers. (+)-Gossypol and (-)-Gossypol binds to Bcl-2 or Bcl-xL with similar binding affinities. (-)-Gossypol is more potent than (+)-Gossypol in inhibition of cell growth and induction of apoptosis. The racemic form and each of the enantiomers of Gossypol are tested against UM-SCC-6 and UM-SCC-14A in 6-day MTT assays. (-)-Gossypol exhibits greater growth inhibition relative to (±)-Gossypol than (+)-Gossypol in both cell lines tested (P<0.001). An intermediate growth inhibitory effect is observed with (±)-Gossypol but this effect is only observed at the higher dose of Gossypol (10 μM, P<0.0001)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

578.61

Formula

C₃₂H₃₄O₁₀

CAS 号

1189561-66-7

性状

固体

颜色

Light yellow to yellow

中文名称

(S)-棉子酚乙酸

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 50 mg/mL (86.41 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7283 mL	8.6414 mL	17.2828 mL
5 mM	0.3457 mL	1.7283 mL	3.4566 mL
10 mM	0.1728 mL	0.8641 mL	1.7283 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.32 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 98.39%

选择批次：

Data Sheet (627 KB) SDS (252 KB)

COA (296 KB) LCMS (96 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Oliver CL, et al. In vitro effects of the BH3 mimetic, (-)-Gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res. 2004 Nov 15;10(22):7757-63. [Content Brief]

Cell Assay	Two representative UM-SCC cell lines, UM-SCC-6 and UM-SCC-14A, are continuously exposed to 0 (vehicle control), 5 or 10 μM (±)-Gossypol, (-)-Gossypol or (S)-Gossypol ((+)-Gossypol) in a 6-day MTT cell survival assay^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Oliver CL, et al. In vitro effects of the BH3 mimetic, (-)-Gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res. 2004 Nov 15;10(22):7757-63. [Content Brief]

(S)-Gossypol (acetic acid) 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7283 mL	8.6414 mL	17.2828 mL	43.2070 mL
	5 mM	0.3457 mL	1.7283 mL	3.4566 mL	8.6414 mL
	10 mM	0.1728 mL	0.8641 mL	1.7283 mL	4.3207 mL
	15 mM	0.1152 mL	0.5761 mL	1.1522 mL	2.8805 mL
	20 mM	0.0864 mL	0.4321 mL	0.8641 mL	2.1603 mL
	25 mM	0.0691 mL	0.3457 mL	0.6913 mL	1.7283 mL
	30 mM	0.0576 mL	0.2880 mL	0.5761 mL	1.4402 mL
	40 mM	0.0432 mL	0.2160 mL	0.4321 mL	1.0802 mL
	50 mM	0.0346 mL	0.1728 mL	0.3457 mL	0.8641 mL
	60 mM	0.0288 mL	0.1440 mL	0.2880 mL	0.7201 mL
	80 mM	0.0216 mL	0.1080 mL	0.2160 mL	0.5401 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(S)-Gossypol (acetic acid)1189561-66-7(S)-(+)-Gossypol acetic acid(S)-棉子酚乙酸Bcl-2 FamilyInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

(S)-Gossypol (acetic acid) (Synonyms: (S)-(+)-Gossypol acetic acid)

Customer Review

Other Forms of (S)-Gossypol (acetic acid):

MCE 顾客使用本产品发表的 3 篇科研文献

(S)-Gossypol (acetic acid) 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Bcl-2 Family 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

(S)-Gossypol (acetic acid) 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

(S)-Gossypol (acetic acid) (Synonyms: (S)-(+)-Gossypol acetic acid)

Customer Review

Other Forms of (S)-Gossypol (acetic acid):

(S)-Gossypol (acetic acid) 相关抗体

MCE 顾客使用本产品发表的 3 篇科研文献

(S)-Gossypol (acetic acid) 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Bcl-2 Family 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

(S)-Gossypol (acetic acid) 相关抗体:

摩尔计算器

稀释计算器

(S)-Gossypol (acetic acid) 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z